BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30903197)

  • 1. Development and validation of the PET-CT score for diagnosis of malignant pleural effusion.
    Yang MF; Tong ZH; Wang Z; Zhang YY; Xu LL; Wang XJ; Li W; Wu XZ; Wang W; Zhang YH; Jiang T; Shi HZ
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1457-1467. PubMed ID: 30903197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PET-CT score for discriminating malignant from benign pleural effusions.
    Simó M; Persiva O; Sánchez L; Montoro B; Vázquez A; Sansano I; Alemán C
    Med Clin (Barc); 2023 Nov; 161(10):422-428. PubMed ID: 37487808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical role of F-18 FDG PET/CT in differentiating malignant and benign pleural effusion in patients with lung cancer].
    Liao R; Yang X; Wang S; Zhou Q; Nie Q; Zhong W; Dong S; Wu Y
    Zhongguo Fei Ai Za Zhi; 2012 Nov; 15(11):652-5. PubMed ID: 23164351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion.
    Gupta NC; Rogers JS; Graeber GM; Gregory JL; Waheed U; Mullet D; Atkins M
    Chest; 2002 Dec; 122(6):1918-24. PubMed ID: 12475827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
    Kim BS; Kim IJ; Kim SJ; Pak K; Kim K
    Onkologie; 2011; 34(6):298-303. PubMed ID: 21625182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Derivation and validation of a CT scan scoring system for discriminating malignant from benign pleural effusions.
    Porcel JM; Pardina M; Bielsa S; González A; Light RW
    Chest; 2015 Feb; 147(2):513-519. PubMed ID: 25255186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.
    Sun Y; Yu H; Ma J; Lu P
    PLoS One; 2016; 11(8):e0161764. PubMed ID: 27560933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is
    Lee SH; Sung C; Lee HS; Yoon HY; Kim SJ; Oh JS; Song JW; Kim MY; Ryu JS
    Ann Nucl Med; 2018 Aug; 32(7):492-498. PubMed ID: 29974372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET of pleural effusions in patients with non-small cell lung cancer.
    Erasmus JJ; McAdams HP; Rossi SE; Goodman PC; Coleman RE; Patz EF
    AJR Am J Roentgenol; 2000 Jul; 175(1):245-9. PubMed ID: 10882281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of PET/CT to the differentiation of benign and malignant pleural effusion in patients with ovarian carcinoma.
    Budak A; Yanarateş A; Budak E
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(6):353-358. PubMed ID: 37172933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis.
    Fjaellegaard K; Koefod Petersen J; Reuter S; Malene Fischer B; Gerke O; Porcel JM; Frost Clementsen P; Laursen CB; Bhatnagar R; Bodtger U
    Lung Cancer; 2021 Dec; 162():106-118. PubMed ID: 34775214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses.
    Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ
    Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management.
    Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP
    Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using neighborhood gray tone difference matrix texture features on dual time point PET/CT images to differentiate malignant from benign FDG-avid solitary pulmonary nodules.
    Chen S; Harmon S; Perk T; Li X; Chen M; Li Y; Jeraj R
    Cancer Imaging; 2019 Aug; 19(1):56. PubMed ID: 31420006
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Taralli S; Scolozzi V; Foti M; Ricciardi S; Forcione AR; Cardillo G; Calcagni ML
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):429-436. PubMed ID: 30535767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of PET/MRI in the diagnosis of malignant pleural effusion in comparison with PET/CT].
    Peng WB; Sun X; Zhou M; Wei XS; Wu XZ; Ruan WW; Shi HZ; Lan XL; Zhou Q
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2363-2369. PubMed ID: 34404128
    [No Abstract]   [Full Text] [Related]  

  • 17. Can dynamic imaging, using
    Marin A; Murchison JT; Skwarski KM; Tavares AAS; Fletcher A; Wallace WA; Salapura V; van Beek EJR; Mirsadraee S
    Radiol Oncol; 2021 May; 55(3):259-267. PubMed ID: 34051709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Derivation and validation of a 18F-FDG PET/CT scoring model to predict malignant pleural effusion.
    Lu P; Sun Y; Liang B; Yu L
    Nucl Med Commun; 2022 Feb; 43(2):177-185. PubMed ID: 34864810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can PET/CT be used more effectively in pleural effusion evaluation?
    Simsek FS; Yuksel D; Yaylali O; Aslan HS; Kılıçarslan E; Bir F; Arslan M; Can FE; Ugurlu E
    Jpn J Radiol; 2021 Dec; 39(12):1186-1194. PubMed ID: 34165683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes].
    Buchmann I; Guhlmann CA; Elsner K; Gfrörer W; Schirrmeister H; Kotzerke J; Buck A; Reske SN
    Nuklearmedizin; 1999; 38(8):319-22. PubMed ID: 10615665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.